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A B S T R A C T
Objective: Chronic obstructive pulmonary disease (COPD) is a progressive disease with
functional decline leading to disability. Dyspnea, the prominent symptom, can be measured
using existing measures, but a lack of consensus about standardization of dyspnea mea-
surement remains. We examined the psychometric performance of two item-response the-
ory–based (IRT) measures of dyspnea and related functional limitations (FLs) in patients
with COPD and simulated computerized adaptive testing (CAT) of the banks to determine
the number of questions required to achieve high precision.
Methods: A total of 102 patients completed banks measuring dyspnea and FLs (33 items), from
which the 10-item dyspnea and FL short forms were scored as well as other self-report measures
of respiratory and physical function and emotional distress. A subset of patients completed the
banks 7 to 10 days later. Pulmonary function test results were obtained from medical charts.
Results: The 33-item banks and 10-item short forms had excellent internal consistency
(alphas 0.9) and test-retest reliability (intraclass correlation coefficients 0.89). Patients
sorted by severity level on the Medical Research Council scale were differentiated by item
banks (P  0.001) and the short forms (P  0.01). The banks and short forms were also
associated with related measures of dyspnea (e.g., Baseline Dyspnea Index, r  0.47–0.53),
physical function (e.g., 36-Item Short Form Health Survey, r  0.83 to 0.86) and forced
expiratory volume in 1 second (r  0.32 to 0.35). On average, CAT required 4 and 5 items
for accurate measurement of dyspnea and FLs, respectively.
Conclusion: The Functional Assessment of Chronic Illness Therapy–Dyspnea short forms
and banks provide options for brief, psychometrically sound measures of dyspnea and/or
FLs in COPD.
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Chronic obstructive pulmonary disease (COPD) is a major public
health problem in the United States, affecting approximately 24
million people and millions more around the world [1]. It is the
fourth leading cause of death in the world and is projected to be
ranked fifth in burden of disease worldwide by the year 2020 [2].
The National Heart, Lung, and Blood Institute of the National
Institutes of Health estimates that the economic burden of COPD
in the United States was $49.9 billion in direct and indirect costs
in 2010 [3]. COPD is also a major source of disability and impaired
health-related quality of life (HRQL) [4].
COPD includes chronic lung diseases (i.e., chronic bronchi-
tis, emphysema) that are characterized by progressive ob-
struction of the airflow into and out of the lungs and increased
dyspnea [5]. It can be extremely disabling and limit an individ-
ual’s function across several important areas including upper
extremity function, balance, strength, exercise performance,
and self-reported daily activities such as vacuuming, climbing
stairs, and engaging in recreation [6]. Clinical evaluations typ-
ically include both pulmonary function tests (PFTs) (e.g., spi-
rometry) and patient-reported symptoms.
The diagnosis of COPD is often confirmed by pulmonary
functioning (e.g., PFTs), including spirometry, which mea-
sures airflow out of fully inflated lungs over time in liters [7].
However, objective measures of pulmonary functioning, such
as PFTs, do not correlate particularly well with patient reports
of COPD-associated symptoms [8]. One of the most prominent
patient-reported symptoms of COPD is dyspnea, a subjective
experience that can only be measured from the patient’s per-
spective. Different people will have different thresholds for
noticing, reporting, and rating the severity of the symptom.
Other factors, such as the level of activity, presence and sever-
ity of comorbid disease, environmental conditions, and anxi-
ety, may influence dyspnea ratings as well. The lack of asso-
ciation with PFTs is, therefore, not surprising. It does,
however, underscore the need for psychometrically sound
measures of dyspnea and related functional limitations (FLs)
for use in clinical trials.
Patient-reported dyspnea, however, has proved difficult to
measure in a comprehensive and psychometrically sound
manner. Several general and disease-specific self-report in-
struments have previously been developed, but criticism in
the research and clinical literature has highlighted an overall
lack of consensus and standardization [9].
Ideally, a measure of dyspnea for use in clinical trials
should be brief, self-administered, standardized, created with
cross-cultural input, easily understood by patients and physi-
cians, and responsive to changes in severity across the disease
spectrum. In response to the noted limitations of existing
measures, we undertook the task of developing a new and
psychometrically improved self-report measure of COPD-re-
lated dyspnea and related FLs. The first task was to construct
a patient-driven conceptual model to elucidate the relation-
ships between dyspnea and other important factors that not
only influence it, but are also influenced by it [10]. This model
served as the basis of our creation of a new self-reported tool
to measure dyspnea and related FLs.We then developed a patient-derived conceptual frame-
work and an item-response theory (IRT)–based item bank of
dyspnea severity and related FLs [11]. To maximize geographic
diversity as well as efficiency of data collection, the frame-
work was tested using an online Internet panel of COPD pa-
tients across the United States, 608 respondents at baseline
and a subset of 236 respondents at 7-10 days’ follow up [11]. By
taking advantage of modern test development approaches,
including IRT [12,13]. we were able to “calibrate” patient item
responses along a severity continuum that represents a given
latent trait, such as dyspnea. A calibrated item bank allows
one to estimate a person’s location along a continuum of in-
creasingly difficult items and determine which items provide
maximum information on a given concept [14,15]. This en-
ables the creation of fixed-length short forms from a pool of
calibrated items as well as computerized adaptive testing
(CAT), a dynamic measurement platform that allows items to
be selected based on an individual’s previous responses. CAT
administration reduces test length dramatically while im-
proving measurement quality [16–18]. This step resulted in
the development of two 33-item item banks for dyspnea and
FLs, and from those banks, a 20-item short-form measure of
dyspnea (10 items) and its FLs (10 items) was created, using a
methodology described elsewhere [11].
As the final step in the development and testing of a new
measure of COPD-related dyspnea and FLs, we now report on
the validity of the 20-item Functional Assessment of Chronic
Illness Therapy (FACIT)–Dyspnea scale, tested with a different
sample of 102 individuals with a diagnosis of COPD who were
obtained from outpatient pulmonary medicine and internal
medicine clinics. The 20 items include 10 that assess dyspnea
severity (Dyspnea-10) and 10 that assess dyspnea related FLs
(FL-10). We compare and contrast the performance of these
two short forms with the item banks for dyspnea and FLs (33
items each) and provide information from a simulated CAT for
consideration by researchers/clinicians when making choices
about method of administration.
Methods
Participants
Patients were eligible for the study if they had a diagnosis of
COPD, were fluent in English, were at least 18 years of age, and
had no current diagnosis of psychosis or dementia. To balance
recruitment between patients with mild versus more severe
dyspnea, patients were recruited from general internal medi-
cine clinics, where those with milder cases of COPD tend to be
seen, as well as specialized pulmonology clinics and a PFT
laboratory, where individuals with more severe COPD tend to
receive their treatment.
Procedure
After the informed consent process, patients completed a so-
ciodemographic questionnaire to obtain basic background in-
formation. Clinical information was obtained from patients
(e.g., diagnosis, smoking history, previous/existing comorbid
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and thorough medical chart review (e.g., PFT results). The most
recent PFT results for each patient were obtained from patients’
medical records. Patients then completed a battery of question-
naires (described later) administered via touch-screen laptop
computer. Seven to 10 days after completion of the baseline
questionnaires, patients completed a brief clinical form to cap-
ture any change in clinical status since baseline and repeated the
dyspnea and FL item banks. If patients were scheduled to return
to the clinic within the assessment window, they completed the
assessments via touch-screen laptop computer; if not, the ques-
tionnaires were completed via telephone interview.
Measures
In addition to completing sociodemographic questionnaires,
patients completed a baseline assessment battery that con-
sisted of the following measures.
FACIT-Dyspnea Item Banks
Patients completed item banks for dyspnea and FLs, each with
33 items [11]. Included in these 33-item banks were the items
that comprise the FACIT-Dyspnea short forms (Dyspnea-10
and FL-10). All dyspnea items include a 4-point rating scale (no
shortness of breath 0; mildly short of breath 1; moderately
short of breath 2; severely short of breath 3; or I did not do
this in the past 7 days  4).
Although respondents in this study did not complete short
forms as stand-alone measures, the forms are constructed so
that respondents are presented with 10 common tasks and
asked to rate the severity of their dyspnea when completing
these tasks over the past 7 days using the same response scale
as the banks. Those who report not doing the task are asked to
report whether it was attributable to dyspnea (shortness of
breath) or simply because they did not have an opportunity to
do the task in the past week. If the response is because of
dyspnea (i.e., “stopped trying” or “knew could not do it be-
cause of shortness of breath”), the response is treated the same
as the response “severely short of breath.” Otherwise, the re-
sponse is treated as missing (i.e., not included for scoring). Next,
using the same 10 items, respondents are asked to rate the
amount of difficulty they experienced when doing these tasks on
a 4-point Likert scale (no difficulty 0; a little difficulty 1; some
difficulty  2; much difficulty  3). Respondents are not pre-
sented with items that were rated as “I did not do” on the dys-
pnea severity subscale; however, those who report dyspnea-re-
lated task avoidance are scored as a 3 (much difficulty) on the FL
subscale, whereas nonexposure task avoiders are not scored.
The FACIT-Dyspnea short forms are scored such that a high
score represents high levels of dyspnea or FLs.
Baseline Dyspnea Index (BDI) [19,20]
The BDI is a multidimensional instrument for measuring
breathlessness based on three aspects of dyspnea: 1) func-
tional impairment, 2) magnitude of task, and 3) magnitude of
effort. The interviewer-administered version of the BDI used
in this study grades the three categories from 0 (severe) to 4
(unimpaired); a baseline focal score ranging from 0 to 12 is
obtained by adding the three individual scores together.Medical Research Council (MRC) Dyspnea Scale [21]
The MRC dyspnea scale consists of five statements about per-
ceived dyspnea, and patients select the grade that applies to
the impact of dyspnea on their mobility: grade 1, “I only get
breathless with strenuous exercise”; grade 2, “I get short of
breath when hurrying on the level or up a slight hill”; grade 3,
“I walk slower than people of the same age on the level be-
cause of breathlessness or have to stop for breath when walk-
ing at my own pace on the level”; grade 4, “I stop for breath
after walking 100 yards or after a few minutes on the level”;
grade 5, “ I am too breathless to leave the house.”
36-Item Short Form Health Survey (SF-36) [22]
The SF-36 is a 36-item questionnaire with eight subscales
(physical functioning, social functioning, role limitations be-
cause of a physical problem, role limitations because of an
emotional problem, mental health, vitality, pain, and general
health perception) and one single item to measure health
change. The eight subscales form two distinct higher order
summary scales: the physical component summary scale, and
the mental summary component scale. Transformed scores
on all scales range from 0 to 100, with higher scores indicating
better HRQL.
Hospital Anxiety and Depression Scale (HADS) [23]
The HADS is a 14-item self-report inventory to measure anx-
iety and depression. The scale consists of seven items for anx-
iety (HADS-A) and seven for depression (HADS-D). The items
are scored on a 4-point scale from 0 (not present) to 3 (consid-
erable). The item scores are summed, yielding subscale scores
on the HADS-A and the HADS-D ranging from 0 to 21.
Chronic Respiratory Questionnaire–Self-Administered
Standardized (CRQ-SAS) Version (CRQ-SAS) [24,25]
The Chronic Respiratory Questionnaire (CRQ) is a respiratory-
specific health status instrument originally developed for pa-
tients with COPD that assesses four aspects of COPD-related
quality of life: dyspnea, fatigue, emotional function, and mas-
tery, each of which is scored on a 7-point Likert-type scale. In
this study, analyses focused on the five-item dyspnea sub-
scale only because that was most relevant to the validation of
the FACIT-Dyspnea scale.
Data analysis
The analyses described in the following were conducted on the
33-item dyspnea and FL banks and the 10-item short forms.
Three respondents with excessive missing responses (90%) on
either of the banks were removed from the analyses.
Reliability
Internal consistency analyses based on baseline data were con-
ducted for the item banks and short forms of the new dyspnea
measure using Cronbach’s alpha coefficients. A Cronbach’s al-
pha of 0.70 or greater was considered necessary to minimally
meet the recommended standards. Test-retest reliability was
evaluated by calculating an ICC for the item banks and short
forms at baseline and 7 to 10 days post-baseline using data from
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have a range of possible values from 0.0 to 1.0.
Discriminant validity
A frequency distribution was calculated on the MRC dyspnea
scale at baseline. Cross-sectional analyses of item bank and
the short form scores at baseline focused on differentiating
definable groups defined according to the MRC dyspnea scale.
We used analysis of variance and/or pairwise t tests to com-
pare mean dyspnea and FL bank and short form scores and
MRC dyspnea scale categories, with the expectation that pa-
tients with higher MRC dyspnea scale scores would report
greater dyspnea/FLs. Effect sizes were calculated for group com-
parisons to provide an indication of the clinical significance of
group differences. We used eta squared (2), which is the propor-
ion of the total variance in scores that is explained by MRC dys-
nea scale categories. For 2, an effect size of 0.14 is considered a
arge effect [26]. For pairwise comparisons of adjacent groups, we
sed Cohen’s d effect size measure. For Cohen’s d, an effect size
f 0.8 and higher is considered a large effect.
Convergent validity
The associations between the item bank and short form
scores, CRQ-SAS dyspnea subscale, HADS, and subscales of
the SF-36 were evaluated using correlational analyses. The
FACIT-Dyspnea scores (banks and short forms) were expected
to be most highly correlated with the CRQ-SAS dyspnea sub-
scale and physical functioning subscales of the SF-36 and cor-
related to a lesser extent with the socioemotional subscales of
the SF-36 and HADS.
Concurrent validity
The association between item bank scores and short form
scores and the BDI scores were evaluated using correlations.
Because the well-established BDI has been extensively used to
assess dyspnea, the dyspnea scores and the BDI scores were
expected to correlate.
Post hoc CAT simulations
CAT simulations can provide useful information regarding the
potential effectiveness of an item bank under CAT adminis-
tration for a population of interest. Thus, we simulated CAT
based on baseline ratings of dyspnea and FLs from the FACIT-
Dyspnea scale (n  99) using the Firestar CAT simulator [27].
The minimum and maximum numbers of items to administer
were set at 3 and 12, respectively, with a minimum standard
error criterion set at 0.3.
Results
Sample
Of the 103 consented participants, 102 reported sociodemo-
graphic data. Three respondents were removed because of ex-
cessive missing responses (fewer than five valid responses). As
described in Table 1, this sample was nearly equally divided in
erms of sex (53% female), it was overwhelmingly non-Hispanic
99%), and the majority were white (85%). The mean (SD) age was70 (10) years, consistent with 63% of the sample being retired.
The participants were overall well educated, with 28% having
some college, 25% college graduates, and 29% having earned a
graduate degree. Twenty percent of the participants reported an
all-source family income of greater than $60,000, and 35% re-
ported a family income of $100,000 or more.
As detailed in Table 2, which describes the sample’s clinical
characteristics, participants reported having a diagnosis of COPD
for a median of 3 years (range: 0–37 years). Fifteen percent of the
sample was smoking at the time of their participation, and 72%
had smoked tobacco products in the past. Participants reported a
range of current and previous comorbid conditions. Ninety per-
cent were using an inhaler, 59% a steroid inhaler, and 22% were
taking oral steroids (45% intermittently, 55% continuously).
Forty-two percent of the sample reported experiencing an exac-
erbation of their COPD less than a month before their study par-
ticipation, 30% had an exacerbation between 1 and 3 months
previously, and 27% more than 3 months before their participa-
tion. The severity of the exacerbations was rated as mild by 56%,
moderate by 26%, and severe by 18%.
Internal consistency reliability
The internal consistency reliability, as measured by Cron-
bach’s alpha (n 99, after removing cases with fewer than five
Table 1 – Sample sociodemographic characteristics
(N = 102).
Variable Value (%)
Age, mean  SD (range) 70  10.3 (40–92)
Sex (male) 48 (47%)
Hispanic/Spanish/Latino origin 1 (1%)
Race/ethnicity
White 87 (85%)
Black 9 (9%)
Other 6 (6%)
Marital status
Married 54 (53%)
Divorced 22 (22%)
Widowed 16 (16%)
Single 10 (10%)
Living arrangement
Alone 34 (33%)
With other adult(s) and/or dependents 68 (67%)
Highest grade in school completed
Less than 12th grade 4 (4%)
High school graduate or equivalent 14 (14%)
Some college 29 (28%)
College grad or advanced degree 55 (54%)
Current occupational status
Homemaker 6 (6%)
Unemployed 2 (2%)
Retired 64 (63%)
On disability 5 (5%)
Full-time or part-time employed 25 (25%)
Family income
$19,999 13 (14%)
$20,000–$39,999 14 (15%)
$40,000–$59,999 15 (16%)
$60,000–$99,999 18 (20%)
$100,000 32 (35%)valid responses on the bank), was 0.973 for the Dyspnea item
3
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Dyspnea-10 and FL-10 were 0.922 and 0.928, respectively.
Test-retest reliability
Test-retest reliability, evaluated by an ICC, showed good mea-
surement stability of the full-length banks and short forms
over 7 to 10 days (n 82). The ICCs were 0.916 and 0.933 for the
3-item dyspnea and FL banks, respectively, and 0.896 and
.912 for Dyspnea-10 and FL-10, respectively.
Discriminant validity
The mean scaled score for each MRC dyspnea scale category
showed a clear linear pattern of escalation across the MRC
Table 2 – Sample clinical characteristics (N = 102).
Variable
Diagnosis (in medical chart)
COPD
Chronic bronchitis
Emphysema
Bronchiectasis
Median no. of years since diagnosis (range)
Smoking history
Currently smoke tobacco
Mean  SD number of years smoked (range)
Smoked tobacco products in the past
Mean  SD number of years smoked (range)
Comorbid medical conditions (top 8 current)
Hypertension
Acid reflux (heartburn)
Arthritis
Back pain
Asthma
Depression
Insomnia
Coronary artery disease
Medications
Use of any inhalers
Use of any steroid inhaler
Taking any oral steroids
Frequency of steroid use
Intermittent
Continuous
Other respiratory medications
Theophylline
Montelukast
Other
Pulmonary function test results (n  58)
Median FEV1/FVC
Median FEV1 percentage predicted
Most recent exacerbation
1 mo ago
Between 1 and 3 mo ago
3 mo ago
Severity of most recent exacerbation
Mild
Moderate
Severe
Use of any assistive devices
COPD, chronic obstructive pulmonary disease; FEV1, forced expiratordyspnea scale categories. Figure 1 graphically displays the be-tween-group mean differences across the categories and the
within-group variations within each category based on the
four measures. The most severe MRC dyspnea scale category
(category 5) contained only four cases and, hence, was com-
bined with the next lower category. Patients in different MRC
categories were characterized by substantially and system-
atically different dyspnea/FL item bank and short form
scores (Dyspnea-33 bank [F3,95  40.02, P  0.001], FL-33
bank [F3,95 40.88, P 0.001], Dypsnea-10 short form [F3,95
5.28, P 0.01], and FL-10 short form (F3,95 37.44, P 0.01]).
Subsequent pairwise comparisons using the Bonferroni
step-down (Holm) correction revealed that the dyspnea/FL
measures distinctly separated each higher category as hav-
ing a substantially higher mean score (P  0.01). The effect
size estimates (using pooled SDs) ranged from 0.811 to
Value (%)
67 (66%)
8 (8%)
29 (28%)
21 (21%)
3 (0–37)
15 (15%)
43  10 (23–60)
73 (72%)
31  14 (2–58)
Current Previous
41 (40%) 44 (44%)
36 (35%) 46 (46%)
37 (36%) 41 (41%)
32 (31%) 45 (45%)
28 (27%) 32 (32%)
17 (17%) 21 (21%)
14 (14%) 15 (15%)
13 (13%) 20 (20%)
92 (90%)
60 (59%)
22 (22%)
10 (45%)
12 (55%)
3 (3%)
8 (8%)
13 (13%)
0.63
58
42 (42%)
30 (30%)
27 (27%)
56 (56%)
26 (26%)
18 (18%)
46 (46%)
ume in 1 second; FVC, forced vital capacity.1.356, indicating mean differences between adjacent cate-
s
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comparisons.
Convergent validity
Table 3 displays the ICCs between dyspnea item bank and
hort form scores and the validity measures (i.e., CRQ-SAS
yspnea, HADS and its subscales, SF-36 subscales and two
omponent scales, and BDI). The correlations are very consis-
ent between the respective banks and short forms. In most
omparisons, the ICC for the 33-item bank was slightly higher
han that of the short form in each domain of dyspnea or FLs.
The dyspnea and FL measures were most highly correlated
with the SF-36 Physical Function scale (0.86 to 0.82) fol-
lowed by the SF-36 Physical Component Scale (0.83 to0.76)
Fig. 1 – The distribution of dyspnea and FL scores by MRC dy
boxes represent the middle 50% of the scores for each MRC
the median, and the upper and lower brackets the maximum
scores with a mean of 0 and an SD of 1.and the CRQ-SAS dyspnea (0.77 to 0.80). The lowest corre-lations were with the SF-36 Emotional Well-being scale (0.35
to 0.39).
The dyspnea bank and short form were significantly corre-
lated with FEV1 percentage predicted (r  0.30, P  0.05; r 
0.33, P  0.05, respectively).
CAT simulation
On average, CAT administered 4.39 and 4.43 items for the dys-
pnea and FL banks, respectively. People at the lower (health-
ier) end of the spectrum were given relatively more items, but
only the four to five most extreme cases exceeded seven
items. With fewer than five items, on average, the CAT gener-
ated scores that were highly correlated with the bank scores;
the correlations between the full bank and CAT were 0.953 for
ea scale categories are graphically displayed. The shaded
nea scale category, the band near the middle of the box
d minimum scores. All scores are expressed as scaledspn
dysp
anboth dyspnea and FLs. The top five most frequently adminis-
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to 20 lb (about 4.5–9 kg, such as a large bag of groceries) from
one room to another, walking 50 steps/paces on flat ground at
a normal speed without stopping, walking up 20 stairs (2
flights) without stopping, walking (faster than your usual
speed) for 0.5 mile (almost 1 km) without stopping, and pre-
paring meals.
Discussion
This study evaluated the reliability and validity of the FACIT-
Dyspnea scale in people with a diagnosis of COPD. The mea-
sures included both the item banks for dyspnea and FLs (33
items each) and the short forms for the same two constructs
(10 items each). In this validation study, patients completed
items from the two banks, and their scores on the 10-item
short forms were calculated as summed subsets of the banks.
The measurement properties of the banks and short forms
were very good. The internal consistency of the banks and
short forms were quite high (0.90), as was the test-retest
reliability over 7 to 10 days (also 0.90). The bank and short
form scores successfully differentiated patients by MRC dys-
pnea scale categories. For both banks and short forms, all
scores across MRC dyspnea scale groups were in the expected
direction, i.e., patients with the lowest MRC dyspnea scale
scores (i.e., better dyspnea status) had the lowest dyspnea/FLs
scores (i.e., better dyspnea/functional status), and those with
higher MRC dyspnea scale scores had FACIT-Dyspnea scores
reflecting poorer dyspnea/FL status. Further, the dyspnea
banks and short forms were correlated in the expected direc-
tion and magnitude with other study measures. Concurrent
validity was demonstrated by the FACIT-Dyspnea measures’
significant correlations with prominent existing measures of
Table 3 – Validity coefficients based on pearson correlation
Validity measures Mean SD
Baseline dyspnea index 6.0 2.3
CRQ-SAS
Dyspnea 27.3 6.3
Fatigue 17.3 5.4
Emotional 37.1 8.3
Mastery 20.9 5.2
HADS 8.9 6.5
HADS-anxiety 4.9 3.8
HADS-depression 4.0 3.4
SF-36
Physical function 34.3 11.5
Role physical 37.4 11.4
Bodily pain 47.0 11.1
General health 38.9 10.7
Vitality 44.7 10.1
Social function 45.0 12.3
Role emotional 38.0 12.1
Mental health 49.7 9.3
Physical component scale 37.4 9.6
Mental component scale 47.7 9.5
CRQ-SAS, Chronic Respiratory Questionnaire–Self-Administered Sta
Depression Scale; SF-36, 36-Item Short Form Health Survey.dyspnea, the BDI (r 0.47–0.52). Evidence of convergent valid- vity was suggested by higher correlations with measures ex-
pected to be more highly related to the FACIT-Dyspnea mea-
sures (e.g., CRQ-SAS dyspnea, SF-36 Physical Function) and
lower correlations with measures of less related constructs
(e.g., HADS-A or -D, SF-36 Social Functioning). Consistent with
the literature [8], the FACIT-Dyspnea measures were more
weakly associated with objective measures of lung function
(r  0.30–0.35 with PFTs). These findings closely mirror those
eported previously with the Internet-based calibration sam-
le of 608 individuals with COPD [11].
We demonstrated that CAT provides an efficient measure-
ent of dyspnea and FLs in a clinical population of patients
ith mild to severe dyspnea. Our post hoc simulations dem-
nstrated that the amount of reduction in test length was sub-
tantial compared to the full-bank and even to the static short
orm. This should be attractive to clinical researchers whose
ajor concern is to minimize burden, especially with patients
ho have physical limitations.
Although a number of self-report dyspnea and respiratory
ealth measures currently exist, they have some important
imitations. We developed a measure that includes aspects of
yspnea that are highly rated by both patients and clinicians;
as developed using a conceptual model and methodology
onsistent with the US Food and Drug Administration (FDA)
RO Guidance [28]; that is patient-completed versus requiring
nterviewer administration or clinician rating; is very brief,
equiring an average of four to five items for each CAT and
0 by static short form; has strong psychometric qualities,
ncluding reflecting differences in severity across the dis-
ase spectrum; and is consistent in its format, context, and
esponse options; thereby addressing the majority the lim-
tations of current instruments [9,19,21,24,29 –39]. In addi-
ion, the FACIT-Dyspnea measures were created with cross-
ultural input, facilitating the eventual development and
fficients (N=99).
pnea-33 Dyspnea-10 FL-33 FL-10
0.51 0.46 0.52 0.52
0.80 0.78 0.79 0.77
0.53 0.52 0.53 0.50
0.43 0.43 0.43 0.40
0.56 0.56 0.54 0.50
0.54 0.53 0.57 0.53
0.44 0.44 0.46 0.45
0.53 0.51 0.57 0.52
0.85 0.82 0.86 0.84
0.58 0.56 0.60 0.56
0.45 0.42 0.49 0.49
0.59 0.57 0.60 0.62
0.59 0.56 0.61 0.58
0.61 0.59 0.64 0.61
0.55 0.55 0.57 0.52
0.39 0.37 0.37 0.35
0.79 0.76 0.83 0.82
0.47 0.46 0.47 0.43
ized version; FL, functional limitation; HADS, Hospital Anxiety andcoe
Dys















ndardalidation in languages other than English. The FACIT-Dys-
314 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 3 0 7 – 3 1 5pnea also offers administration options, depending on prefer-
ence and logistical constraints, which include fixed-length
short forms as well as CAT.
This study is not without limitations. One factor that was
largely related to the geographic location of the participating
hospitals was the sex and age of the participants who were
recruited using convenience sampling at one suburban and
one urban health care setting. The sample was largely white,
well-educated, and relatively affluent, which is likely not rep-
resentative of the US population with COPD. A second poten-
tial limitation is the sample size of 102 participants with
COPD. This limits the degree to which the results that we re-
port are generalizable to the larger population of individuals
with COPD. In addition, a relatively small subsample had
available PFT data in their medical charts (n 58), which could
have resulted in inadequate power to detect a significant as-
sociation with the FACIT-Dyspnea measures. Even though one
of the strengths of this new tool is its flexibility in application
as CAT, the simulations that were conducted are only the first
step toward this tool’s validated use, and future studies
should prospectively seek to validate this CAT in different
clinical samples. Finally, this study reported on cross-sec-
tional results only; future studies will be needed to assess the
measures’ ability to detect responsiveness longitudinally.
The set of FACIT-Dyspnea measures now offers clinical tri-
alists, clinical researchers, and clinicians options for selecting
brief, psychometrically sound measures of dyspnea and/or
FLs and was developed in accordance with the FDA PRO Guid-
ance to satisfy regulatory concerns. Future studies will be im-
portant to demonstrate the measures’ psychometric perfor-
mance in larger, more diverse populations of individuals with
COPD.
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